Calimmune Appoints Mark Smith as Chief Financial Officer

TUCSON, Ariz.–(BUSINESS WIRE)–Calimmune Inc., a clinical-stage gene therapy company, has expanded its
leadership team with the appointment of Mark Smith as chief financial
officer. Mr. Smith brings more than 20 years of operational, financial
and transactional experience to the position, in which he will oversee
all financial operations and transactional activities for the company
worldwide.

“Mark is an accomplished finance executive who, throughout his career,
has successfully navigated a variety of strategic transactions,
including private and public financings, mergers and acquisitions,
corporate partnerships and debt financings,” said Louis Breton, chief
executive officer of Calimmune. “His deep business acumen further rounds
out Calimmune’s growing leadership team, providing added strength as we
continue to expand our gene therapy platform into novel application
areas and advance our clinical programs.”

Mr. Smith has helped guide and grow companies in the life science,
medical device and renewable biofuels sectors, most recently serving as
CFO at Fluidic Energy. Previously, he held the same role for Gevo, where
he played a key role in the company’s $123 million initial public
offering. He also held the CFO post for biotech firm Replidyne during
its initial public offering through its 2009 sale to Cardiovascular
Systems, and has served in various financial executive capacities at
healthcare companies including Nabi Biopharmaceuticals, Neuromedical
Systems, Genzyme Corp. and Genetrix. He began his career with
PricewaterhouseCoopers, holding accounting roles in Australia and the
U.S. Mr. Smith holds a bachelor’s degree in accounting from the
University of Canberra, Australia.

About Calimmune

Calimmune Inc. is a clinical-stage, international biotechnology company
focused on developing novel gene therapies that have the potential to
improve and protect the lives of patients by enhancing their immune
system. The company was founded in 2006 from technology developed in the
labs of Nobel Laureate David Baltimore, Ph.D. (California Institute of
Technology), Irvin Chen, Ph.D. (University of California, Los Angeles)
and Inder M. Verma, Ph.D. (Salk Institute for Biological Studies).
Calimmune’s lead product candidate for HIV, now in Phase I/II studies,
is being evaluated as a one-time treatment to prevent HIV progression to
AIDS. The company is headquartered in Tucson, Arizona, with labs and
branch offices in Pasadena, California, and Sydney, Australia.

Contacts

Calimmune Inc.
Casey Sankey, 310-806-6240 x105
Director of
Communications
mediarelations@calimmuneinc.com
or
Canale
Communications
Mark Corbae, 619-849-5375
Vice President
mark@canalecomm.com